In this ASH 2023 interview, Dr. Jos Melenhorst discusses a collaborative study on single-cell multi-omics in pediatric ALL patients. The research aims to predict long-term responses to anti-CD19 CAR T cells by analyzing gene expression profiles.
Dr. Melenhorst reveals a cytogram profile linked to B cell replacement, a key remission biomarker. The interview explores correlations in CAR T cells’ functionality, emphasizing the potential for manipulation to enhance efficacy. Insights from a mouse model underscore the importance of the type 2 pathway in sustaining remission, offering perspectives for CAR T therapy development.